Chinese authorities refused to provide World Health Organization investigators with raw, personalized data on early Covid-19 cases that could help them determine how and when the coronavirus first began to spread in China, the Wall Street Journal reported, citing WHO investigators.
A Covid-19 vaccine being developed by CSL Ltd. and the University of Queensland was scrapped after numerous vaccine recipients reported receiving false positives on certain HIV tests, according to the Wall Street Journal.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 17-4 to recommend Pfizer and BioNTech’s Covid-19 vaccine for Emergency Use Authorization (EUA) for individuals ages 16 years and older.
The Wall Street Journal reported that at least six pharmaceutical companies working on vaccines and therapeutics for Covid-19 were targeted by North Korean hackers
A settlement valued at $8.34 billion was reached between Purdue Pharmaand the Justice Department, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin, according to the Wall Street Journal.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.
Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.
Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.
Becton Dickinson is investigating reports from U.S. nursing homes that the company’s rapid coronavirus testing equipment is producing false-positive results.
Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.